Failed molecular targets push glioma research toward immunotherapy and biomarkers

Failed molecular targets push glioma research toward immunotherapy and biomarkers
Image: Intellect (generated)

In short: A review of glioma research found that classic molecular targets such as p53, retinoblastoma, and EGFR have failed as treatments due to tumors' complex regulatory networks. The authors describe emerging approaches, including immunotherapy, tumor microenvironment targeting, and biomarker-guided personalized treatment, as promising directions for aggressive brain tumors such as glioblastoma.

Gliomas are common brain tumors with outcomes that vary widely by molecular subtype, and the current standard for glioblastoma is surgery followed by radiotherapy and chemotherapy. This review argues that growing interest in immune-based therapies and biomarkers could lead to more personalized treatment options.

As a review of existing literature rather than a new experiment, it does not provide new patient data or trial results, and it calls for more pre-clinical and clinical trials to test these targets and biomarkers.

Why it matters: Understanding why past glioma treatments failed is guiding a shift toward immune-based and personalized therapies.

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

To cite this card, link to https://intellectplus.co.uk/app/science-research-identifying-new-molecular-targets-to-improve-treatment-for-c.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…